Published in FEMS Microbiol Rev on January 27, 2014
Enzymatic modifications of exopolysaccharides enhance bacterial persistence. Front Microbiol (2015) 0.91
Crossroads between Bacterial and Mammalian Glycosyltransferases. Front Immunol (2014) 0.84
Engineered heparins as new anticoagulant drugs. Bioeng Transl Med (2016) 0.81
Heparin and related polysaccharides: synthesis using recombinant enzymes and metabolic engineering. Appl Microbiol Biotechnol (2015) 0.80
Depolymerase improves gentamicin efficacy during Klebsiella pneumoniae induced murine infection. BMC Infect Dis (2014) 0.80
Metabolic Reprogramming of Host Cells by Virulent Francisella tularensis for Optimal Replication and Modulation of Inflammation. J Immunol (2016) 0.80
Deletion of a 77-base-pair inverted repeat element alters the synthesis of surface polysaccharides in Porphyromonas gingivalis. J Bacteriol (2015) 0.79
The Type of Growth Medium Affects the Presence of a Mycobacterial Capsule and Is Associated With Differences in Protective Efficacy of BCG Vaccination Against Mycobacterium tuberculosis. J Infect Dis (2016) 0.78
Bioengineered heparins and heparan sulfates. Adv Drug Deliv Rev (2015) 0.78
Infections and Systemic Lupus Erythematosus: Binding or Sparring Partners? Int J Mol Sci (2015) 0.77
Bacterial glycobiology: rhamnose-containing cell wall polysaccharides in Gram-positive bacteria. FEMS Microbiol Rev (2016) 0.77
Cyclic AMP (cAMP) Receptor Protein-cAMP Complex Regulates Heparosan Production in Escherichia coli Strain Nissle 1917. Appl Environ Microbiol (2015) 0.77
Heparin: Past, Present, and Future. Pharmaceuticals (Basel) (2016) 0.77
Utilizing complement evasion strategies to design complement-based antibacterial immunotherapeutics: Lessons from the pathogenic Neisseriae. Immunobiology (2016) 0.75
SDS-PAGE Analysis of the Outer Membrane Proteins of Uropathogenic Escherichia coli Isolated from Patients in Different Wards of Nemazee Hospital, Shiraz, Iran. Iran J Med Sci (2016) 0.75
Coordination of Metabolism and Virulence Factors Expression of Extraintestinal Pathogenic Escherichia coli Purified from Blood Cultures of Patients with Sepsis. Mol Cell Proteomics (2016) 0.75
Single polysaccharide assembly protein that integrates polymerization, termination, and chain-length quality control. Proc Natl Acad Sci U S A (2017) 0.75
Anergic B Cells: Precarious On-Call Warriors at the Nexus of Autoimmunity and False-Flagged Pathogens. Front Immunol (2015) 0.75
Ultrastructural Changes in Clinical and Microbiota Isolates of Klebsiella pneumoniae Carriers of Genes bla SHV, bla TEM, bla CTX-M, or bla KPC When Subject to β-Lactam Antibiotics. ScientificWorldJournal (2015) 0.75
E. coli Group 1 Capsular Polysaccharide Exportation Nanomachinary as a Plausible Antivirulence Target in the Perspective of Emerging Antimicrobial Resistance. Front Microbiol (2017) 0.75
Bacteriophage-encoded virion-associated enzymes to overcome the carbohydrate barriers during the infection process. Appl Microbiol Biotechnol (2017) 0.75
Identification of a chondroitin synthase from an unexpected source, the green sulfur bacterium Chlorobium phaeobacteroides. Glycobiology (2017) 0.75
Evaluation of the Immunomodulatory Properties of Streptococcus suis and Group B Streptococcus Capsular Polysaccharides on the Humoral Response. Pathogens (2017) 0.75
THE SOLUBLE SPECIFIC SUBSTANCE OF PNEUMOCOCCUS. J Exp Med (1923) 32.69
A synthetic oscillatory network of transcriptional regulators. Nature (2000) 24.58
Pathogenic Escherichia coli. Nat Rev Microbiol (2004) 17.81
Bacterial biofilms in nature and disease. Annu Rev Microbiol (1987) 16.14
Serology, chemistry, and genetics of O and K antigens of Escherichia coli. Bacteriol Rev (1977) 13.47
A SEROLOGICAL DIFFERENTIATION OF HUMAN AND OTHER GROUPS OF HEMOLYTIC STREPTOCOCCI. J Exp Med (1933) 10.79
What is flux balance analysis? Nat Biotechnol (2010) 9.01
Escherichia coli K1 capsular polysaccharide associated with neonatal meningitis. N Engl J Med (1974) 7.89
Heparin-protein interactions. Angew Chem Int Ed Engl (2002) 7.27
Virulence factors in Escherichia coli urinary tract infection. Clin Microbiol Rev (1991) 7.11
Synthetic biology: applications come of age. Nat Rev Genet (2010) 6.96
Hyaluronan. FASEB J (1992) 6.67
Influence of the Escherichia coli capsule on complement fixation and on phagocytosis and killing by human phagocytes. J Clin Invest (1980) 6.61
Epidemiology of Escherichia coli K1 in healthy and diseased newborns. Lancet (1975) 6.25
Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet (1983) 5.63
A synchronized quorum of genetic clocks. Nature (2010) 5.47
Biosynthesis and assembly of capsular polysaccharides in Escherichia coli. Annu Rev Biochem (2006) 5.41
Bacteriophage therapy. Antimicrob Agents Chemother (2001) 5.16
Identification of genes subject to positive selection in uropathogenic strains of Escherichia coli: a comparative genomics approach. Proc Natl Acad Sci U S A (2006) 5.13
The multicellular morphotypes of Salmonella typhimurium and Escherichia coli produce cellulose as the second component of the extracellular matrix. Mol Microbiol (2001) 5.07
The biochemistry and genetics of capsular polysaccharide production in bacteria. Annu Rev Microbiol (1996) 4.13
Structure, assembly and regulation of expression of capsules in Escherichia coli. Mol Microbiol (1999) 4.05
Serotypes, hemolysin production, and receptor recognition of Escherichia coli strains associated with neonatal sepsis and meningitis. Infect Immun (1985) 4.01
The pgaABCD locus of Escherichia coli promotes the synthesis of a polysaccharide adhesin required for biofilm formation. J Bacteriol (2004) 3.73
Cell-surface glycosaminoglycans. Annu Rev Biochem (1984) 3.68
Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci. Proc Natl Acad Sci U S A (1991) 3.60
Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat Rev Microbiol (2010) 3.45
High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. Nature (2013) 3.32
Influence of encapsulation on staphylococcal opsonization and phagocytosis by human polymorphonuclear leukocytes. Infect Immun (1978) 3.23
Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci. J Immunol (1982) 3.23
Immunology of Escherichia coli: K antigen and its relation to urinary-tract infection. J Infect Dis (1973) 3.02
Escherichia coli serotyping and disease in man and animals. Can J Microbiol (1992) 2.94
Frequency of E. coli K antigens in urinary-tract infections in children. Lancet (1977) 2.89
Form variation in Escherichia coli K1: determined by O-acetylation of the capsular polysaccharide. J Exp Med (1979) 2.89
Polysaccharide processing and presentation by the MHCII pathway. Cell (2004) 2.88
Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci U S A (2007) 2.87
Evidence for a common molecular origin of the capsule gene loci in gram-negative bacteria expressing group II capsular polysaccharides. Mol Microbiol (1991) 2.86
The structure of the capsular polysaccharide (K5 antigen) of urinary-tract-infective Escherichia coli 010:K5:H4. A polymer similar to desulfo-heparin. Eur J Biochem (1981) 2.84
Origins and virulence mechanisms of uropathogenic Escherichia coli. Exp Mol Pathol (2008) 2.81
Genetic parts to program bacteria. Curr Opin Biotechnol (2006) 2.78
Single-molecule approaches to stochastic gene expression. Annu Rev Biophys (2009) 2.75
Protein secretion in Bacillus species. Microbiol Rev (1993) 2.74
Evolutionary considerations in relating oligosaccharide diversity to biological function. Glycobiology (1999) 2.67
Proteomics of protein secretion by Bacillus subtilis: separating the "secrets" of the secretome. Microbiol Mol Biol Rev (2004) 2.67
Structure and biosynthesis of the capsular antigens of Escherichia coli. Curr Top Microbiol Immunol (1990) 2.64
CsrA post-transcriptionally represses pgaABCD, responsible for synthesis of a biofilm polysaccharide adhesin of Escherichia coli. Mol Microbiol (2005) 2.61
Hyaluronic acid capsule and the role of streptococcal entry into keratinocytes in invasive skin infection. J Clin Invest (1996) 2.57
Spontaneous mutations in the CsrRS two-component regulatory system of Streptococcus pyogenes result in enhanced virulence in a murine model of skin and soft tissue infection. J Infect Dis (2001) 2.51
NZB mouse system for production of monoclonal antibodies to weak bacterial antigens: isolation of an IgG antibody to the polysaccharide capsules of Escherichia coli K1 and group B meningococci. Proc Natl Acad Sci U S A (1985) 2.49
Some characteristics of Escherichia coli strains isolated from extraintestinal infections of humans. J Infect Dis (1978) 2.40
Polysialic acid in the plasticity of the developing and adult vertebrate nervous system. Nat Rev Neurosci (2008) 2.40
The love-hate relationship between bacterial polysaccharides and the host immune system. Nat Rev Immunol (2006) 2.31
Uropathogenic properties of Escherichia coli in recurrent urinary-tract infection. J Med Microbiol (1980) 2.28
Role of the capsule and the O antigen in resistance of O18:K1 Escherichia coli to complement-mediated killing. Infect Immun (1983) 2.24
Recombinant protein secretion in Escherichia coli. Biotechnol Adv (2005) 2.23
Molecular cloning and analysis of genes for production of K5, K7, K12, and K92 capsular polysaccharides in Escherichia coli. J Bacteriol (1986) 2.23
Coordinate regulation of glycan degradation and polysaccharide capsule biosynthesis by a prominent human gut symbiont. J Biol Chem (2009) 2.21
The role of bacterial polysaccharide capsules as virulence factors. Curr Top Microbiol Immunol (1990) 2.18
Molecular cloning, identification, and sequence of the hyaluronan synthase gene from group A Streptococcus pyogenes. J Biol Chem (1993) 2.17
Proposed mechanisms for the translocation of intestinal bacteria. Rev Infect Dis (1988) 2.16
Molecular cloning of the K1 capsular polysaccharide genes of E. coli. Nature (1981) 2.15
Structural variation in the glycan strands of bacterial peptidoglycan. FEMS Microbiol Rev (2007) 2.15
Role of glycosaminoglycans in cellular communication. Acc Chem Res (2004) 2.14
Towards understanding molecular modes of probiotic action. Curr Opin Biotechnol (2006) 2.14
Definition of a bacterial virulence factor: sialylation of the group B streptococcal capsule. Proc Natl Acad Sci U S A (1989) 2.13
Occurrence of unique polysialosyl carbohydrate units in glycoproteins of developing brain. J Biol Chem (1982) 2.09
Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation. Infect Immun (1987) 2.09
Capsular K1 polysaccharide of Escherichia coli: relationship to virulence in newborn rats and resistance to phagocytosis. Infect Immun (1979) 2.08
The role of complement in the host's defense against Streptococcus pneumoniae. Rev Infect Dis (1981) 2.06
Characterization of group C and G streptococcal strains that cause streptococcal toxic shock syndrome. J Clin Microbiol (2004) 2.00
Genetic analysis of chromosomal mutations in the polysialic acid gene cluster of Escherichia coli K1. J Bacteriol (1989) 1.97
Polysialylation: from bacteria to brains. Glycobiology (1992) 1.97
Advances in the biology and chemistry of sialic acids. ACS Chem Biol (2010) 1.96
Genetic organization of Pasteurella multocida cap Loci and development of a multiplex capsular PCR typing system. J Clin Microbiol (2001) 1.93
Analytical applications of aptamers. Biosens Bioelectron (2004) 1.93
Natural and experimental infection with an attaching and effacing strain of Escherichia coli in calves. Infect Immun (1986) 1.87
Cross-antigenicity and immunogenicity between capsular polysaccharides of group C Neisseria meningitidis and of Escherichia coli K92. J Infect Dis (1977) 1.84
Contribution of genes from the capsule gene complex (cps) to lipooligosaccharide biosynthesis and serum resistance in Neisseria meningitidis. Mol Microbiol (1994) 1.82
Polysaccharide lyases. Appl Biochem Biotechnol (1986) 1.81
Hyaluronic acid synthesis operon (has) expression in group A streptococci. J Biol Chem (1995) 1.81
The extended family of proteoglycans: social residents of the pericellular zone. Curr Opin Cell Biol (1989) 1.81
Identification of two genes, kpsM and kpsT, in region 3 of the polysialic acid gene cluster of Escherichia coli K1. J Bacteriol (1991) 1.77
Molecular analysis of the Escherichia coli K5 kps locus: identification and characterization of an inner-membrane capsular polysaccharide transport system. Mol Microbiol (1990) 1.77
Group A Streptococcus tissue invasion by CD44-mediated cell signalling. Nature (2001) 1.76
Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J Immunol (1998) 1.75
The biologic significance of bacterial encapsulation. Curr Top Microbiol Immunol (1990) 1.72
Chondroitin/dermatan sulfate in the central nervous system. Curr Opin Struct Biol (2007) 1.67
A molecular-capsular-type prediction system for 90 Streptococcus pneumoniae serotypes using partial cpsA-cpsB sequencing and wzy- or wzx-specific PCR. J Med Microbiol (2005) 1.67
Immunology of bacterial polysaccharide antigens. Carbohydr Res (2003) 1.67
Nothing in glycobiology makes sense, except in the light of evolution. Cell (2006) 1.66
E. coli K5 fermentation and the preparation of heparosan, a bioengineered heparin precursor. Biotechnol Bioeng (2010) 1.65
Chemoenzymatic design of heparan sulfate oligosaccharides. J Biol Chem (2010) 1.64
Determinant specificities of the groups B and C polysaccharides of Neisseria meningitidis. J Immunol (1985) 1.60
Bacterial glycans: key mediators of diverse host immune responses. Cell (2006) 1.57
Molecular analysis of region 1 of the Escherichia coli K5 antigen gene cluster: a region encoding proteins involved in cell surface expression of capsular polysaccharide. J Bacteriol (1993) 1.56
A new subfamily of bacterial ABC-type transport systems catalyzing export of drugs and carbohydrates. Protein Sci (1992) 1.56
Group a streptococcal diseases and their global burden. Curr Top Microbiol Immunol (2013) 1.56
Polysaccharide antigens of Escherichia coli. Rev Infect Dis (1988) 1.56
Restricted complement activation by Escherichia coli with the K-1 capsular serotype: a possible role in pathogenicity. J Immunol (1978) 1.54
Heparin-protein interactions. Angew Chem Int Ed Engl (2002) 7.27
Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol (2008) 4.46
Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol (2007) 3.73
Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem (2003) 2.94
Lessons learned from the contamination of heparin. Nat Prod Rep (2009) 2.81
Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins. Science (2011) 2.79
Structural and genetic diversity of group B streptococcus capsular polysaccharides. Infect Immun (2005) 2.51
Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology (2005) 2.46
The proteoglycan bikunin has a defined sequence. Nat Chem Biol (2011) 2.14
Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain. Genes Dev (2005) 2.10
Solution structures of chemoenzymatically synthesized heparin and its precursors. J Am Chem Soc (2008) 2.02
Flexible energy storage devices based on nanocomposite paper. Proc Natl Acad Sci U S A (2007) 2.02
Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Hum Mol Genet (2004) 1.92
Electron detachment dissociation of glycosaminoglycan tetrasaccharides. J Am Soc Mass Spectrom (2006) 1.89
Enzymatic redesigning of biologically active heparan sulfate. J Biol Chem (2005) 1.89
Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol (2006) 1.71
Heparin-binding domains in vascular biology. Arterioscler Thromb Vasc Biol (2004) 1.71
Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc Natl Acad Sci U S A (2004) 1.70
Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity. Hum Mol Genet (2003) 1.66
E. coli K5 fermentation and the preparation of heparosan, a bioengineered heparin precursor. Biotechnol Bioeng (2010) 1.65
Chemoenzymatic design of heparan sulfate oligosaccharides. J Biol Chem (2010) 1.64
Distinguishing glucuronic from iduronic acid in glycosaminoglycan tetrasaccharides by using electron detachment dissociation. Anal Chem (2007) 1.61
Characterization of a heparan sulfate octasaccharide that binds to herpes simplex virus type 1 glycoprotein D. J Biol Chem (2002) 1.53
Modular optimization of multi-gene pathways for fatty acids production in E. coli. Nat Commun (2013) 1.52
Liquid chromatography/mass spectrometry sequencing approach for highly sulfated heparin-derived oligosaccharides. J Biol Chem (2003) 1.51
Engineering central metabolic pathways for high-level flavonoid production in Escherichia coli. Appl Environ Microbiol (2007) 1.46
Glycomics of proteoglycan biosynthesis in murine embryonic stem cell differentiation. J Proteome Res (2007) 1.46
Ionic liquid-mediated selective extraction of lignin from wood leading to enhanced enzymatic cellulose hydrolysis. Biotechnol Bioeng (2009) 1.46
Quantification of heparan sulfate disaccharides using ion-pairing reversed-phase microflow high-performance liquid chromatography with electrospray ionization trap mass spectrometry. Anal Chem (2009) 1.45
Identification and characterization of a glycosaminoglycan recognition element of the C chemokine lymphotactin. J Biol Chem (2004) 1.42
Disaccharide analysis of glycosaminoglycan mixtures by ultra-high-performance liquid chromatography-mass spectrometry. J Chromatogr A (2011) 1.42
Genome-scale metabolic network modeling results in minimal interventions that cooperatively force carbon flux towards malonyl-CoA. Metab Eng (2011) 1.42
Biosynthesis of natural flavanones in Saccharomyces cerevisiae. Appl Environ Microbiol (2005) 1.42
Structural analysis of the sulfotransferase (3-o-sulfotransferase isoform 3) involved in the biosynthesis of an entry receptor for herpes simplex virus 1. J Biol Chem (2004) 1.41
Electron detachment dissociation of dermatan sulfate oligosaccharides. J Am Soc Mass Spectrom (2007) 1.40
Influence of charge state and sodium cationization on the electron detachment dissociation and infrared multiphoton dissociation of glycosaminoglycan oligosaccharides. J Am Soc Mass Spectrom (2008) 1.40
Negative electron transfer dissociation of glycosaminoglycans. Anal Chem (2010) 1.39
Crystal structure and mutational analysis of heparan sulfate 3-O-sulfotransferase isoform 1. J Biol Chem (2004) 1.38
Toll-like receptor 4 mediates induction of the Bcl10-NFkappaB-interleukin-8 inflammatory pathway by carrageenan in human intestinal epithelial cells. J Biol Chem (2008) 1.38
Structural analysis of bikunin glycosaminoglycan. J Am Chem Soc (2008) 1.37
Orthogonal analytical approaches to detect potential contaminants in heparin. Proc Natl Acad Sci U S A (2009) 1.36
Strain improvement of recombinant Escherichia coli for efficient production of plant flavonoids. Mol Pharm (2008) 1.34
Control of the heparosan N-deacetylation leads to an improved bioengineered heparin. Appl Microbiol Biotechnol (2011) 1.33
Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly. Biochemistry (2004) 1.33
Heparin accelerates gelsolin amyloidogenesis. Biochemistry (2006) 1.31
Room temperature ionic liquids as emerging solvents for the pretreatment of lignocellulosic biomass. Biotechnol Bioeng (2011) 1.31
Analysis of E. coli K5 capsular polysaccharide heparosan. Anal Bioanal Chem (2010) 1.30
Enzymatic synthesis of heparin related polysaccharides on sensor chips: rapid screening of heparin-protein interactions. Biochem Biophys Res Commun (2005) 1.29
Ultra-performance ion-pairing liquid chromatography with on-line electrospray ion trap mass spectrometry for heparin disaccharide analysis. Anal Biochem (2011) 1.28
Improving NADPH availability for natural product biosynthesis in Escherichia coli by metabolic engineering. Metab Eng (2009) 1.27
Microscale isolation and analysis of heparin from plasma using an anion-exchange spin column. Anal Biochem (2006) 1.27
Top-down approach for the direct characterization of low molecular weight heparins using LC-FT-MS. Anal Chem (2012) 1.26
Metabolic engineering for plant natural product biosynthesis in microbes. Curr Opin Biotechnol (2008) 1.26
Recent chemical and enzymatic approaches to the synthesis of glycosaminoglycan oligosaccharides. Curr Med Chem (2003) 1.25
Proteoglycomics: recent progress and future challenges. OMICS (2010) 1.25
Heparin mapping using heparin lyases and the generation of a novel low molecular weight heparin. J Med Chem (2010) 1.24
Electron-induced dissociation of glycosaminoglycan tetrasaccharides. J Am Soc Mass Spectrom (2008) 1.23
The structure of chondroitin B lyase complexed with glycosaminoglycan oligosaccharides unravels a calcium-dependent catalytic machinery. J Biol Chem (2004) 1.23
Kinetic studies on the interactions of heparin and complement proteins using surface plasmon resonance. Biochim Biophys Acta (2005) 1.22
Using a 3-O-sulfated heparin octasaccharide to inhibit the entry of herpes simplex virus type 1. Biochemistry (2008) 1.21
High-yield resveratrol production in engineered Escherichia coli. Appl Environ Microbiol (2011) 1.21
Identification of the capsular polysaccharides of Type D and F Pasteurella multocida as unmodified heparin and chondroitin, respectively. Carbohydr Res (2002) 1.20
Preparation of biopolymer fibers by electrospinning from room temperature ionic liquids. Biomacromolecules (2006) 1.19
Biosynthesis and biotechnological production of flavanones: current state and perspectives. Appl Microbiol Biotechnol (2009) 1.19
Increased malonyl coenzyme A biosynthesis by tuning the Escherichia coli metabolic network and its application to flavanone production. Appl Environ Microbiol (2009) 1.19
Engineering of routes to heparin and related polysaccharides. Appl Microbiol Biotechnol (2011) 1.19
Structural characterization of human liver heparan sulfate. Biochim Biophys Acta (2004) 1.18
Biosynthesis of isoprenoids, polyunsaturated fatty acids and flavonoids in Saccharomyces cerevisiae. Microb Cell Fact (2006) 1.17
Analysis of pharmaceutical heparins and potential contaminants using (1)H-NMR and PAGE. J Pharm Sci (2009) 1.16
Isolation and characterization of heparan sulfate from various murine tissues. Glycoconj J (2006) 1.15
Immobilization of heparin: approaches and applications. Curr Top Med Chem (2008) 1.14
High-resolution crystal structure of Arthrobacter aurescens chondroitin AC lyase: an enzyme-substrate complex defines the catalytic mechanism. J Mol Biol (2004) 1.14
Metabolic engineering of anthocyanin biosynthesis in Escherichia coli. Appl Environ Microbiol (2005) 1.13
Analysis of mutations in fibroblast growth factor (FGF) and a pathogenic mutation in FGF receptor (FGFR) provides direct evidence for the symmetric two-end model for FGFR dimerization. Mol Cell Biol (2005) 1.13
Synthesis of gold and silver nanoparticles stabilized with glycosaminoglycans having distinctive biological activities. Biomacromolecules (2009) 1.12
Oversulfated chondroitin sulfate interaction with heparin-binding proteins: new insights into adverse reactions from contaminated heparins. Biochem Pharmacol (2009) 1.12
Dissecting the substrate recognition of 3-O-sulfotransferase for the biosynthesis of anticoagulant heparin. Proc Natl Acad Sci U S A (2012) 1.11
Cell-bound IL-8 increases in bronchial epithelial cells after arylsulfatase B silencing due to sequestration with chondroitin-4-sulfate. Am J Respir Cell Mol Biol (2009) 1.11
Heparinase 1 selectivity for the 3,6-di-O-sulfo-2-deoxy-2-sulfamido-alpha-D-glucopyranose (1,4) 2-O-sulfo-alpha-L-idopyranosyluronic acid (GlcNS3S6S-IdoA2S) linkages. Glycobiology (2010) 1.11
Oversulfated chondroitin sulfate: impact of a heparin impurity, associated with adverse clinical events, on low-molecular-weight heparin preparation. J Med Chem (2008) 1.11
Ultraperformance liquid chromatography with electrospray ionization ion trap mass spectrometry for chondroitin disaccharide analysis. Anal Biochem (2009) 1.10
Complete mass spectral characterization of a synthetic ultralow-molecular-weight heparin using collision-induced dissociation. Anal Chem (2012) 1.10
Kinetic and structural studies on interactions between heparin or heparan sulfate and proteins of the hedgehog signaling pathway. Biochemistry (2007) 1.10
Recent progress and applications in glycosaminoglycan and heparin research. Curr Opin Chem Biol (2009) 1.10
Compositional analysis of heparin/heparan sulfate interacting with fibroblast growth factor.fibroblast growth factor receptor complexes. Biochemistry (2009) 1.09
HSulf-1 modulates FGF2- and hypoxia-mediated migration and invasion of breast cancer cells. Cancer Res (2011) 1.09
Metabolic engineering of Chinese hamster ovary cells: towards a bioengineered heparin. Metab Eng (2012) 1.09
Gold and silver nanoparticles conjugated with heparin derivative possess anti-angiogenesis properties. Nanotechnology (2009) 1.08
Structural characterization of pharmaceutical heparins prepared from different animal tissues. J Pharm Sci (2013) 1.08
Functional expression of a P450 flavonoid hydroxylase for the biosynthesis of plant-specific hydroxylated flavonols in Escherichia coli. Metab Eng (2005) 1.08
Structural characterization of glycosaminoglycans from zebrafish in different ages. Glycoconj J (2008) 1.08
Structural characterization of heparins from different commercial sources. Anal Bioanal Chem (2011) 1.07
Carbon inhibits vascular endothelial growth factor- and fibroblast growth factor-promoted angiogenesis. FEBS Lett (2007) 1.07
High-performance liquid chromatography-mass spectrometry for mapping and sequencing glycosaminoglycan-derived oligosaccharides. Nat Protoc (2010) 1.07
Separation of a complex mixture of heparin-derived oligosaccharides using reversed-phase high-performance liquid chromatography. J Chromatogr A (2003) 1.06
High-resolution preparative separation of glycosaminoglycan oligosaccharides by polyacrylamide gel electrophoresis. Anal Biochem (2010) 1.06
Further evidence that periodate cleavage of heparin occurs primarily through the antithrombin binding site. Carbohydr Res (2002) 1.05
Mosquito heparan sulfate and its potential role in malaria infection and transmission. J Biol Chem (2007) 1.05
Toward an artificial Golgi: redesigning the biological activities of heparan sulfate on a digital microfluidic chip. J Am Chem Soc (2009) 1.04
Glycosaminoglycans in infectious disease. Biol Rev Camb Philos Soc (2013) 1.04